Abstract
We included 852 patients in a prospectively recruiting multicenter matched case-control study in Germany to assess vaccine effectiveness (VE) in preventing COVID-19-associated hospitalization during the Delta-variant dominance. The two-dose VE was 89% (95% CI 84-93%) overall, 79% in patients with more than two comorbidities and 77% in adults aged 60-75years. A third dose increased the VE to more than 93% in all patient-subgroups.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call